Van Hulle, Carol
Ince, Selvi
Okonkwo, Ozioma C.
Bendlin, Barbara B.
Johnson, Sterling C. http://orcid.org/0000-0002-8501-545X
Carlsson, Cynthia M.
Asthana, Sanjay
Love, Seth
Blennow, Kaj http://orcid.org/0000-0002-1890-4193
Zetterberg, Henrik http://orcid.org/0000-0003-3930-4354
Scott Miners, J. http://orcid.org/0000-0001-8594-1640
Funding for this research was provided by:
Alzheimer’s Research UK (ARUK-SRF2019A-001)
Article History
Received: 4 April 2023
Revised: 12 November 2023
Accepted: 5 December 2023
First Online: 5 January 2024
Competing interests
: HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). All other authors have no competing interests to disclose.